Minimal Clinically Important Difference on Parkinson's Disease Sleep Scale 2nd Version

被引:23
作者
Horvath, Krisztina [1 ]
Aschermann, Zsuzsanna [2 ]
Acs, Peter [2 ]
Deli, Gabriella [2 ]
Janszky, Jozsef [2 ,3 ]
Komoly, Samuel [2 ]
Karadi, Kazmer [2 ]
Kovacs, Marton [1 ]
Makkos, Attila [1 ]
Faludi, Bela [2 ]
Kovacs, Norbert [2 ,3 ]
机构
[1] Univ Pecs, Doctoral Sch Clin Neurosci, H-7623 Pecs, Hungary
[2] Univ Pecs, Dept Neurol, H-7623 Pecs, Hungary
[3] MTA PTE Clin Neurosci MR Res Grp, H-7623 Pecs, Hungary
关键词
QUALITY-OF-LIFE; POST-HOC ANALYSIS; NONMOTOR SYMPTOMS; INTESTINAL GEL; IMPACT; INDEX;
D O I
10.1155/2015/970534
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Aims. The aim of the present study was to determine the estimates of minimal clinically important difference for Parkinson's Disease Sleep Scale 2nd version (PDSS-2) total score and dimensions. Methods. The subject population consisted of 413 PD patients. At baseline, MDS-UPDRS, Hoehn-Yahr Scale, Mattis Dementia Rating Scale, and PDSS-2 were assessed. Nine months later the PDSS-2 was reevaluated with the Patient-Reported Global Impression Improvement Scale. Both anchor-based techniques (within patients' score change method and sensitivity-and specificity-basedmethod by receiver operating characteristic analysis) and distribution-based approaches (effect size calculations) were utilized to determine the magnitude of minimal clinically important difference. Results. According to our results, any improvements larger than -3.44 points or worsening larger than 2.07 points can represent clinically important changes for the patients. These thresholds have the effect size of 0.21 and -0.21, respectively. Conclusions. Minimal clinically important differences are the smallest change of scores that are subjectively meaningful to patients. Studies using the PDSS-2 as outcome measure should utilize the threshold of -3.44 points for detecting improvement or the threshold of 2.07 points for observing worsening.
引用
收藏
页数:8
相关论文
共 33 条
  • [1] [Anonymous], 1969, Third symposium on Parkinsons disease
  • [2] Bilateral Subthalamic Stimulation can Improve Sleep Quality in Parkinson's Disease
    Deli, Gabriella
    Aschermann, Zsuzsanna
    Acs, Peter
    Bosnyak, Edit
    Janszky, Jozsef
    Faludi, Bela
    Makkos, Attila
    Kovacs, Marton
    Komoly, Samuel
    Balas, Istvan
    Doczi, Tamas
    Kovacs, Norbert
    [J]. JOURNAL OF PARKINSONS DISEASE, 2015, 5 (02) : 361 - 368
  • [3] Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline
    Ghys, Liesbet
    Surmann, Erwin
    Whitesides, John
    Boroojerdi, Babak
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (13) : 1985 - 1998
  • [4] Movement disorder society task force report on the Hoehn and Yahr staging scale: Status and recommendations
    Goetz, CG
    Poewe, W
    Rascol, O
    Sampaio, C
    Stebbins, GT
    Counsell, C
    Giladi, N
    Holloway, RG
    Moore, CG
    Wenning, GK
    Yahr, MD
    Seidl, L
    [J]. MOVEMENT DISORDERS, 2004, 19 (09) : 1020 - 1028
  • [5] Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results
    Goetz, Christopher G.
    Tilley, Barbara C.
    Shaftman, Stephanie R.
    Stebbins, Glenn T.
    Fahn, Stanley
    Martinez-Martin, Pablo
    Poewe, Werner
    Sampaio, Cristina
    Stern, Matthew B.
    Dodel, Richard
    Dubois, Bruno
    Holloway, Robert
    Jankovic, Joseph
    Kulisevsky, Jaime
    Lang, Anthony E.
    Lees, Andrew
    Leurgans, Sue
    LeWitt, Peter A.
    Nyenhuis, David
    Olanow, C. Warren
    Rascol, Olivier
    Schrag, Anette
    Teresi, Jeanne A.
    van Hilten, Jacobus J.
    LaPelle, Nancy
    [J]. MOVEMENT DISORDERS, 2008, 23 (15) : 2129 - 2170
  • [6] Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release
    Hauser, Robert A.
    Gordon, Mark Forrest
    Mizuno, Yoshikuni
    Poewe, Werner
    Barone, Paolo
    Schapira, Anthony H.
    Rascol, Olivier
    Debieuvre, Catherine
    Fraessdorf, Andmandy
    [J]. PARKINSONS DISEASE, 2014, 2014
  • [7] Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease
    Hauser, Robert A.
    Auinger, Peggy
    [J]. MOVEMENT DISORDERS, 2011, 26 (05) : 813 - 818
  • [8] PARKINSONISM - ONSET PROGRESSION AND MORTALITY
    HOEHN, MM
    YAHR, MD
    [J]. NEUROLOGY, 1967, 17 (05) : 427 - &
  • [9] Horváth K, 2014, IDEGGYOGY SZEMLE, V67, P129
  • [10] Is the MDS-UPDRS a Good Screening Tool for Detecting Sleep Problems and Daytime Sleepiness in Parkinson's Disease?
    Horvath, Krisztina
    Aschermann, Zsuzsanna
    Acs, Peter
    Bosnyak, Edit
    Deli, Gabriella
    Pal, Endre
    Janszky, Jozsef
    Faludi, Bela
    Kesmarki, Ildiko
    Komoly, Samuel
    Bokor, Magdolna
    Rigo, Eszter
    Lajtos, Julia
    Klivenyi, Peter
    Dibo, Gyorgy
    Vecsei, Laszlo
    Takats, Annamaria
    Toth, Adrian
    Imre, Piroska
    Nagy, Ferenc
    Herceg, Mihaly
    Kamondi, Anita
    Hidasi, Eszter
    Kovacs, Norbert
    [J]. PARKINSONS DISEASE, 2014, 2014